These results suggest that targeting B cells can increase immune activity and improve NAT effectiveness, especially in HER2+ and TNBC breast cancer.[51, 52] Further enrichment analysis of these modules indicated the biological relevance of these imaging features in capturing tumor immune heterogeneity.[53, 54, 55, 56] These findings provide a clearer biological basis for our model and identify potential therapeutic targets for breast cancer. Here, ERBB2 is linked to breast cancer.